Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Marc Lasry’s Top Q4 Moves From Avenue Management’s Last 13F

Page 1 of 2

The correction in crude oil and natural gas prices over the past many months has made several investors wary of investing in the energy sector. However, there are also a few investors, including billionaire Marc Lasry, who views these declines as an opportunity to bet big on the energy sector. In his last few interviews, Mr. Lasry has mentioned several times that he sees a huge opportunity in oil & gas and also revealed that his firm, Avenue Capital, is capitalizing on it by purchasing debt that sees a coupon of around 12%. The New York-based fund was founded by Mr. Lasry with his sister, Sonia Gardner, in 1995 with $7 million of their own capital and, in the last 20 years, it has grown to around $12 billion in assets under management (AUM). Avenue Capital recently has submitted its latest 13F filing with the SEC for the reporting period ended December 31, in which it disclosed an equity portfolio worth $622.5 million. In this article we are going to discuss five notable moves from Avenue’s latest filing.

We track hedge funds and other prominent investors because our research has shown that historically their stock picks delivered superior risk-adjusted returns. This is especially true in the small-cap space, where our research showed that a retail investor can generate substantial returns by imitating the most popular picks among smart money investors (see more details here).

Marc Lasry
Marc Lasry
Avenue Capital

Let’s start with Scorpio Bulkers Inc (NYSE:SALT), in which Avenue Capital reduced its stake by 35% to 781,577 shares during the fourth quarter and disclosed a stake worth $7.73 million. The decline in commodity prices over the past several months raised concerns about the survival of most dry-bulk shipping companies, including Scorpio Bulkers Inc (NYSE:SALT). The company lost 50% of its market capitalization last year, and it has slid by 80% since the beginning of 2016. Last year, when shares of the company continuously traded below the $1 mark for 30 days, the New York Stock Exchange (NYSE) sent a letter to the company informing it that it was no longer in compliance with the NYSE’s listing rules. To continue its listing, Scorpio Bulkers went for a 1-for-12 reverse stock split on December 31.

Hovnanian Enterprises, Inc. (NYSE:HOV) is another stock in Avenue Capital’s equity portfolio that has declined by over 75% since the start of 2015. Although the fund reduced its stake in the company by 19% during the fourth quarter, it still held over 5 million shares of Hovnanian Enterprises, Inc. (NYSE:HOV) worth $9.25 million at the end of that period. Despite the company having negative equity and negative liquidation value, a few of the analysts who track the stock are bullish on it, citing the growth in its profitability and revenue. However, most analysts who cover the stock are not optimistic about the company’s future, their main argument being that the Hovnanian Enterprises, Inc. (NYSE:HOV) has over $2 billion in long term debt, while its cash and cash equivalents are only a few millions and its market capitalization is only $225 million. Ken Griffin‘s Citadel Investment Group also cut its stake in Hovnanian Enterprises by 97% to 81,004 shares during the fourth quarter.

Follow Hovnanian Enterprises Inc (NYSE:HOV)
Trade (NYSE:HOV) Now!

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!